A Multicenter Trial of the Efficacy and Safety of a New Formulation of Ibuprofen 800 mg Every 6 Hours in the Management of Postoperative Pain

A Multicenter, Randomized, Double-blind, and Parallel Groups, Placebo-controlled Trial of the Efficacy and Safety of a New Formulation of Ibuprofen 800 mg Every 6 Hours in the Management of Postoperative Pain.

The purpose of this study is to study the efficacy of intravenous administration of ibuprofen compared to placebo in patients with postoperative pain and evaluate its tolerability and safety profile.

Study Overview

• Status: Terminated
• Conditions: Postoperative Pain
• Intervention / Treatment: Drug: Intravenous ibuprofen; Drug: Saline solution

Detailed Description

This is a phase III, national, multicenter, randomized, double-blind, parallel groups, and placebo-controlled.

Patients will be randomized to receive either ibuprofen or placebo. Stratified randomization will be used to assign eligible patients to a stratum according to type of surgery and centre. Randomization sequence will be generated in the coordinating centre.

Blinding of the patient and study personnel evaluating response will be warranted by adequate drug labelling.

All patients will receive morphine administered by patient controlled analgesia (PCA) following a similar schedule in all centres: 1 mg bolus dose with a close time of 5 min and a maximum of 10 mg in an hour and a maximum of 30 mg in 4 hours.

• Study Type: Interventional
• Enrollment (Actual): 231
• Phase: Phase 3

Contacts and Locations

Study Locations

• Spain
  • La Coruña, Spain, 15001
    • Complejo Hospitalario Universitario de A Coruña
  • Lleida, Spain, 25198
    • Hospital Arnau de Vilanova de Lleida
  • Madrid, Spain, 28040
    • Fundacion Jimenez Diaz
  • Madrid, Spain, 28041
    • Hospital 12 de Octubre
  • Madrid, Spain, 28006
    • Hospital La Princesa
  • Madrid, Spain, 28660
    • Hospital de Montepríncipe
  • Pamplona, Spain, 31008
    • Clinica Universitaria de Navarra
  • Toledo, Spain, 45005
    • Hospital Virgen de la Salud
  • Valencia, Spain, 46026
    • Hospital la Fé
  • Valladolid, Spain, 47005
    • Hospital Clínico de Valladolid
  • Madrid
    • Móstoles, Madrid, Spain, 28935
      • Hospital De Mostoles
  • Pontevedra
    • Vigo, Pontevedra, Spain, 15781
      • Hospital Xeral Cies de Vigo
  • Vizcaya
    • Barakaldo, Vizcaya, Spain, 48903
      • Hospital de Cruces

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Men or women between 18 and 80 years old.
2. Being scheduled for elective single surgical site orthopaedic surgery (hip or knee joint replacement, corsed ligaments, column or shoulder surgery), or abdominal surgery (inguinal hernia, cholecystectomy, eventration or hiatus hernia)
3. Being scheduled for general anaesthesia or regional anesthesia without regional analgesia after surgery.
4. Having anticipated need for postoperative narcotic analgesia administered by patient controlled analgesia (PCA).
5. Expected to stay at the hospital for at least 24 h.
6. Providing written informed consent for participating in this study.

Exclusion Criteria:

1. Use of NSAID within 12 hours prior to the first planned dose.
2. Taking oral anticoagulants, lithium, combination of ACE inhibitors, furosemide or aspirin.
3. Anaemia (haemoglobin <10 g/dl) and/or history or evidence of asthma or heart failure.
4. History of allergy or hypersensitivity to any component of IV ibuprofen, aspirin or aspirin related products, NSAID or COX-2 inhibitors.
5. Pregnant or nursing.
6. Weight less than 40 kg.
7. History of severe head trauma that required hospitalization, intracranial surgery or stroke within the previous 30 days, or any history of intracerebral arteriovenous malformation, cerebral aneurism or CNS mass lesion.
8. History of congenital bleeding diathesis or any active clinically significant bleeding or underlying platelet dysfunction.
9. Gastrointestinal bleeding that required medical intervention.
10. Platelet count less than 80.000 determined within the 28 days prior to surgery.
11. Pre-existing dependence on narcotics or receiving chronic treatment with opioids.
12. Severe renal failure (calculated creatinine clearance < 60 ml/min).
13. Liver failure, ALAT or ASAT >3 times upper limit of normality, or bilirubin >2 g/dl.
14. Diagnosed of Bowel Inflammatory Disease.
15. Not able to understand the requirements of the study, or to abide by the study restrictions or to return for the required assessments.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 800 mg intravenous ibuprofen; Treatment group: 800 mg IV ibuprofen, starting at the moment of skin closure and every 6 hours, infused over 15 minutes.	Drug: Intravenous ibuprofen; Treatment group: 800 mg IV ibuprofen, starting at the moment of skin closure and every 6 hours up to 72 hours after the first dose. All patients will receive morphine administered by patient controlled analgesia (PCA). Investigation treatment will be administered every 6 hours until 24 h in abdominal surgery, 48 h in hip surgery and 72 h in knee surgery.; Other Names: IV ibuprofen
Placebo Comparator: 200 ml of saline solution; Placebo group: 200 ml of saline solution, starting at the moment of skin closure and every 6 hours, infused over 15 min.	Drug: Saline solution; Placebo group: 200 ml of saline solution, starting at the moment of skin closure and every 6 hours up to 72 hours after the first dose. All patients will receive morphine administered by patient controlled analgesia (PCA). Investigation treatment will be administered every 6 hours until 24 h in abdominal surgery, 48 h in hip surgery and 72 h in knee surgery.; Other Names: Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluate the efficacy of intravenous ibuprofen for the management of postoperative pain in comparison to placebo	The primary efficacy endpoint will be the reduction in total morphine use in the first 24 hours post- surgery as compared to placebo.	First 24 hours post- surgery

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Secondary efficacy endpoints	- Consumption of morphine in the first 48 h (and 72) hours post- surgery.	From 0 hours to 72 hours post- surgery
Secondary efficacy endpoints	- Pain intensity at rest and with movement measured with the eleven points visual analogue scale (VAS), at 1 and 3 hours and every 6 hours thereafter up to hour 24 h, and then every 8 h up to 6 hour after the last ibuprofen dose.	From 0 hours to 72 hours post- surgery
Secondary efficacy endpoints	- Ramsay-Hunt sedation scale.	From 0 hours to 72 hours post- surgery
Secondary efficacy endpoints	- Time to first subsequent narcotic analgesia (or time to treatment failure).	From 0 hours to 72 hours post- surgery
Secondary efficacy endpoints	- Number of doses of morphine and number of attempts of dosing at PCA	From 0 hours to 72 hours post- surgery
Secondary tolerability and safety endpoints	- Report of adverse events (AEs) during the study	From 0 hours to 72 hours post- surgery
Secondary tolerability and safety endpoints	- Local reactions due to IV infusion (pain, erythema, phlebitis)	From 0 hours to 72 hours post- surgery
Secondary tolerability and safety endpoints	- Vital signs (heart rate, blood pressure, temperature) at 1, 3, 6 hour after the initial dose and every 8 hours thereafter.	From 0 hours to 72 hours post- surgery
Secondary tolerability and safety endpoints	- Routine laboratory tests (chemistry, haematology and coagulation) at baseline and within 24 hours after the last dose.	From 0 hours to 72 hours post- surgery

Collaborators and Investigators

• Sponsor: Biomendi S.A.U.
• Collaborators: Pivotal S.L.
• Investigators: Study Chair: Concepción Pérez, MD, Hospital La Princesa; Study Chair: Francisco Abad, MD, Hospital La Princesa; Study Chair: Dolores Ochoa, MD, Hospital La Princesa; Study Chair: Antonio Planas, MD, Hospital La Princesa

Study record dates

Study Major Dates

• Study Start: May 1, 2012
• Primary Completion (Actual): June 1, 2014
• Study Completion (Actual): July 1, 2014

Study Registration Dates

• First Submitted: September 25, 2014
• First Submitted That Met QC Criteria: October 1, 2014
• First Posted (Estimate): October 2, 2014

Study Record Updates

• Last Update Posted (Estimate): October 2, 2014
• Last Update Submitted That Met QC Criteria: October 1, 2014
• Last Verified: September 1, 2014

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Postoperative Complications; Pain; Neurologic Manifestations; Pain, Postoperative; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Enzyme Inhibitors; Analgesics; Sensory System Agents; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Cyclooxygenase Inhibitors; Ibuprofen
• Other Study ID Numbers: BIBEC02